New synthetic antithrombotic agents for venous thromboembolism: Pentasaccharides, direct thrombin inhibitors, direct Xa inhibitors

Clinics in Chest Medicine

Volumn 31, Issue 4, 2010, Pages 707-718

  Morris, Timothy A ^a  

^a UCSD MEDICAL CENTER   (United States)

Author keywords

Anticoagulation; Management; Pulmonary embolism; Venous thromboembolism

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; DABIGATRAN ETEXILATE; ENOXAPARIN; FONDAPARINUX; HEPARIN; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; PENTASACCHARIDE; PLACEBO; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; HEPARIN INDUCED THROMBOCYTOPENIA; HIP FRACTURE; HUMAN; KNEE ARTHROPLASTY; LUNG EMBOLISM; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SIDE EFFECT; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; BENZAMIDES; BENZIMIDAZOLES; BETA-ALANINE; HUMANS; MORPHOLINES; OLIGOSACCHARIDES; POLYSACCHARIDES; PYRAZOLES; PYRIDINES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 78049476607     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2010.06.006     Document Type: Review

References (57)

1. Chong B.H. Heparin-induced thrombocytopenia. J Thromb Haemost 2003, 1:1471-1478.
2. Amiral J. Antigens involved in heparin-induced thrombocytopenia. Semin Hematol 1999, 36:7-11.
3. Newman P.M., Chong B.H. Further characterization of antibody and antigen in heparin-induced thrombocytopenia. Br J Haematol 1999, 107:303-309.
4. Amiral J., Pouplard C., Vissac A.M., et al. Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation. Br J Haematol 2000, 109:336-341.
5. Horsewood P., Kelton J.G. Investigation of a platelet factor 4 polymorphism on the immune response in patients with heparin-induced thrombocytopenia. Platelets 2000, 11:23-27.
6. Ahmad S., Walenga J.M., Jeske W.P., et al. Functional heterogeneity of antiheparin-platelet factor 4 antibodies: implications in the pathogenesis of the HIT syndrome. Clin Appl Thromb Hemost 1999, 5(Suppl 1):S32-S37.
7. Ziporen L., Li Z.Q., Park K.S., et al. Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. Blood 1998, 92:3250-3259.
8. Horsewood P., Warkentin T.E., Hayward C.P., et al. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol 1996, 95:161-167.
9. Pouplard C., Amiral J., Borg J.Y., et al. Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium. Br J Haematol 1997, 99:273-280.
10. Horne M.K., Alkins B.R. Platelet binding of IgG from patients with heparin-induced thrombocytopenia. J Lab Clin Med 1996, 127:435-442. [see comments].
11. Morris T.A., Castrejon S., Devendra G., et al. No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular-weight heparin or unfractionated heparin: a meta-analysis. Chest 2007, 132:1131-1139.
12. Wallis D.E., Workman D.L., Lewis B.E., et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999, 106:629-635.
13. Warkentin T.E., Greinacher A., Koster A., et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008, 133:340S-380S.
14. Lewis B.E., Wallis D.E., Leya F., et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003, 163:1849-1856.
15. Lam L.H., Silbert J.E., Rosenberg R.D. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun JID -0372516 1976, 69:570-577.
16. Harenberg J. Pharmacology of low molecular weight heparins. Semin Thromb Hemost 1990, 16(Suppl):12-18.
17. Olson S.T., Bjork I., Sheffer R., et al. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem JID -2985121R 1992, 267:12528-12538.
18. Beguin S., Choay J., Hemker H.C. The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb Haemost 1989, 61:397-401.
19. Herbert J.M., Herault J.P., Bernat A., et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998, 91:4197-4205.
20. Hirsh J., Levine M.N. Low molecular weight heparin. Blood 1992, 79:1-17.
21. Morris T.A., Jacobson A., Marsh J.J., et al. Pharmacokinetics of UH and LMWH are similar with respect to antithrombin activity. Thromb Res 2005, 115:45-51.
22. Kearon C., Ginsberg J.S., Julian J.A., et al. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006, 296:935-942.
23. Bauer K.A., Eriksson B.I., Lassen M.R., et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med JID -0255562 2001, 345:1305-1310.
24. Eriksson B.I., Bauer K.A., Lassen M.R., et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001, 345:1298-1304.
25. Lassen M.R., Bauer K.A., Eriksson B.I., et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet JID -2985213R 2002, 359:1715-1720.
26. Turpie A.G., Bauer K.A., Eriksson B.I., et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet JID -2985213R 2002, 359:1721-1726.
27. Eriksson B.I., Lassen M.R. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003, 163:1337-1342.
28. Buller H.R., Davidson B.L., Decousus H., et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004, 140:867-873.
29. Buller H.R., Davidson B.L., Decousus H., et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003, 349:1695-1702.
30. Prescribing label for ARIXTRA, NDA no. 021345. Approved 12/23/2009, in Administration FaD (ed), 2009.
31. Warkentin T.E., Maurer B.T., Aster R.H. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007, 356:2653-2655. [discussion 2655].
32. Rota E., Bazzan M., Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost 2008, 99:779-781.
33. Samama M.M., Gerotziafas G.T. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb Res 2003, 109:1-11.
34. Buller H.R., Cohen A.T., Davidson B., et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007, 357:1094-1104.
35. Buller H.R., Cohen A.T., Davidson B., et al. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 2007, 357:1105-1112.
36. Paty I., Trellu M., Destors J.M., et al. Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion. J Thromb Haemost 2010, 8(4):722-729.
37. Hauel N.H., Nar H., Priepke H., et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002, 45:1757-1766.
38. Eriksson B.I., Dahl O.E., Rosencher N., et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007, 370:949-956.
39. Eriksson B.I., Dahl O.E., Rosencher N., et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007, 5:2178-2185.
40. Ginsberg J.S., Davidson B.L., Comp P.C., et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009, 24:1-9.
41. Schulman S., Kearon C., Kakkar A.K., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361:2342-2352.
42. Schulman S., Wahlander K., Lundstrom T., et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003, 349:1713-1721.
43. Roehrig S., Straub A., Pohlmann J., et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 2005, 48:5900-5908.
44. Perzborn E., Strassburger J., Wilmen A., et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005, 3:514-521.
45. Mueck W., Borris L.C., Dahl O.E., et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008, 100:453-461.
46. Mueck W., Eriksson B.I., Bauer K.A., et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008, 47:203-216.
47. Eriksson B.I., Borris L.C., Friedman R.J., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008, 358:2765-2775.
48. Kakkar A.K., Brenner B., Dahl O.E., et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008, 372:31-39.
49. Lassen M.R., Ageno W., Borris L.C., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008, 358:2776-2786.
50. Agnelli G., Gallus A., Goldhaber S.Z., et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation 2007, 116:180-187.
51. Buller H.R., Lensing A.W., Prins M.H., et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008, 112:2242-2247.
52. Pinto D.J., Orwat M.J., Koch S., et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrah ydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2007, 50:5339-5356.
53. Raghavan N., Frost C.E., Yu Z., et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009, 37:74-81.
54. Lassen M.R., Raskob G.E., Gallus A., et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009, 361:594-604.
55. Buller H., Deitchman D., Prins M., et al. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008, 6:1313-1318.
56. Zhang P., Huang W., Wang L., et al. Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N, N-dimethylcarbamimidoyl)benzamido)-5-meth oxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor. Bioorg Med Chem Lett 2009, 19:2179-2185.
57. Turpie A.G., Bauer K.A., Davidson B.L., et al. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost 2009, 101:68-76.